Skip to main content

Performance of p16INK4a ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study.

Publication ,  Journal Article
Wu, TJ; Smith-McCune, K; Reuschenbach, M; von Knebel Doeberitz, M; Maloba, M; Huchko, MJ
Published in: BMJ Open
September 13, 2016

OBJECTIVE: A biomarker with increased specificity for cervical dysplasia compared with human papillomavirus (HPV) testing would be an attractive option for cervical cancer screening among HIV-infected women in resource-limited settings. p16(INK4a) has been explored as a biomarker for screening in general populations. DESIGN: A 2-year cross-sectional study. SETTING: 2 large HIV primary care clinics in western Kenya. PARTICIPANTS: 1054 HIV-infected women in western Kenya undergoing cervical cancer screening as part of routine HIV care from October 2010 to November 2012. INTERVENTIONS: Participants underwent p16(INK4a) specimen collection and colposcopy. Lesions with unsatisfactory colposcopy or suspicious for cervical intraepithelial neoplasia 2+ (CIN2+; including CIN2/3 or invasive cervical cancer) were biopsied. Following biopsy, disease status was determined by histopathological diagnosis. PRIMARY AND SECONDARY OUTCOME MEASURES: We measured the sensitivity, specificity and predictive values of p16(INK4a) ELISA for CIN2+ detection among HIV-infected women and compared them to the test characteristics of current screening methods used in general as well as HIV-infected populations. RESULTS: Average p16(INK4a) concentration in cervical samples was 37.4 U/mL. After colposcopically directed biopsy, 127 (12%) women were determined to have CIN2+. Receiver operating characteristic analysis showed an area under the curve of 0.664 for p16(INK4a) to detect biopsy-proven CIN2+. At a p16(INK4a) cut-off level of 9 U/mL, sensitivity, specificity, positive and negative predictive values were 89.0%, 22.9%, 13.6% and 93.8%, respectively. The overall p16(INK4a) positivity at a cut-off level of 9 U/mL was 828 (78.6%) women. There were 325 (30.8%) cases of correct p16(INK4a) prediction to detect or rule out CIN2+, and 729 (69.2%) cases of incorrect p16(INK4a) prediction. CONCLUSIONS: p16(INK4a) ELISA did not perform well as a screening test for CIN2+ detection among HIV-infected women due to low specificity. Our study contributes to the ongoing search for a more specific alternative to HPV testing for CIN2+ detection.

Duke Scholars

Published In

BMJ Open

DOI

EISSN

2044-6055

Publication Date

September 13, 2016

Volume

6

Issue

9

Start / End Page

e012547

Location

England

Related Subject Headings

  • Uterine Cervical Neoplasms
  • Uterine Cervical Dysplasia
  • Sensitivity and Specificity
  • ROC Curve
  • Pregnancy
  • Predictive Value of Tests
  • Papillomavirus Infections
  • Logistic Models
  • Kenya
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wu, T. J., Smith-McCune, K., Reuschenbach, M., von Knebel Doeberitz, M., Maloba, M., & Huchko, M. J. (2016). Performance of p16INK4a ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study. BMJ Open, 6(9), e012547. https://doi.org/10.1136/bmjopen-2016-012547
Wu, Tara J., Karen Smith-McCune, Miriam Reuschenbach, Magnus von Knebel Doeberitz, May Maloba, and Megan J. Huchko. “Performance of p16INK4a ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study.BMJ Open 6, no. 9 (September 13, 2016): e012547. https://doi.org/10.1136/bmjopen-2016-012547.
Wu TJ, Smith-McCune K, Reuschenbach M, von Knebel Doeberitz M, Maloba M, Huchko MJ. Performance of p16INK4a ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study. BMJ Open. 2016 Sep 13;6(9):e012547.
Wu, Tara J., et al. “Performance of p16INK4a ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study.BMJ Open, vol. 6, no. 9, Sept. 2016, p. e012547. Pubmed, doi:10.1136/bmjopen-2016-012547.
Wu TJ, Smith-McCune K, Reuschenbach M, von Knebel Doeberitz M, Maloba M, Huchko MJ. Performance of p16INK4a ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study. BMJ Open. 2016 Sep 13;6(9):e012547.

Published In

BMJ Open

DOI

EISSN

2044-6055

Publication Date

September 13, 2016

Volume

6

Issue

9

Start / End Page

e012547

Location

England

Related Subject Headings

  • Uterine Cervical Neoplasms
  • Uterine Cervical Dysplasia
  • Sensitivity and Specificity
  • ROC Curve
  • Pregnancy
  • Predictive Value of Tests
  • Papillomavirus Infections
  • Logistic Models
  • Kenya
  • Humans